Sunday 13 July 2014
Blinatumomab (MT103) is a anti-CD19 drug that has anti-cancer properties. It belongs to a new class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells.
Blinatumomab specifically targets the CD19 antigen present on B cells.
The drug was developed by a German-American company Micromet, Inc. in cooperation with Lonza.